Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention (OPTIENOX-PCI)

Coronary Artery Disease Clinical Trial

— OPTIENOX-PCI  

Official title:

Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03145675
• Other study ID #: PUMCH-2016-2.24
• Secondary ID: JS-1286
• Status: Completed
• Phase: Phase 4
• Start date: May 12, 2017
• Est. completion date: July 14, 2022

Study information

• Verified date: October 2022
• Source: Peking Union Medical College Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The OPTIENOX-PCI is a single-center, prospective, randomized, open-label, controlled study, which is designed to assess the anticoagulation profile of: 1) High-dose (0.75 mg/kg) vs. Standard-dose (0.5 mg/kg) enoxaparin; 2) Staged-dose (0.5+0.25 mg/kg) vs. Single-dose (0.75 mg/kg) enoxaparin in about 376 patients who plan to undergo elective trans-radial coronary angiography (CAG) with or without subsequent percutaneous coronary intervention (PCI).

Description:

Once the radial sheaths are successfully inserted, eligible patients will be consecutively, sequentially, and randomly assigned in a 1:1 ratio and with a block size of 4 to either the Planned Single-dose group (0.75 mg/kg) or the Planned Staged-dose group (0.5 ± 0.25 mg/kg).

The first dose enoxaparin will be administered immediately after randomization. In the Planned Single-dose group, enoxaparin 0.75 mg/kg will be given to all patients before CAG irrespective of whether they will undergo subsequent PCI or not. In the Planned Staged-dose group, enoxaparin 0.5 mg/kg will be administered to all patients before CAG and additional 0.25 mg/kg will be given only to those who will undergo subsequent PCI immediately before PCI.

Trans-radial CAG will be performed immediately after the first dose enoxaparin is given. When the angiographic results are available, whether the patients will proceed to subsequent PCI or not will be at the discretion of the procedure operators, who are blinded to the assignment of enoxaparin dosing regimens. Patients who undergo CAG alone in each group will be defined as the High-dose (0.75 mg/kg) and the Standard-dose (0.5 mg/kg) groups, respectively; while, patients who undergo both CAG and subsequent PCI in each group will be defined as the Single-dose PCI (0.75 mg/kg) and the Staged-dose PCI (0.5 + 0.25 mg/kg) groups, respectively.

Anti-Xa levels will be assessed: 1) at 0 min (immediately before), 10 min and 90 min after the first dose enoxaparin is given (CAG-0 min, CAG-10 min, and CAG-90 min, respectively) in all patients; 2) at 0 min (immediately before) and 10 min after the beginning of PCI (PCI-0 min and PCI-10 min, respectively), and at the end of PCI (PCI-End) in patients undergoing PCI.

Target anticoagulation is defined as: 1) anti-Xa level of 0.5-1.8 IU/ml in patients in the High-dose and Standard-dose groups; 2) anti-Xa level of 0.5-1.2 IU/ml before PCI and anti-Xa level of 0.5-1.8 IU/ml from the beginning of PCI up to 90 min after the first dose enoxaparin is given in the Single-dose PCI and the Staged-dose PCI groups.

The information on cardiac ischemic and bleeding events will be collected 24 h after randomization.

The OPTIENOX-PCI study will assess the anticoagulation profile between: 1) the High-dose and the Standard-dose groups (0.75 mg/kg vs. 0.5 mg/kg); 2) the Staged-dose PCI and the Single-dose PCI groups (0.5+0.25 mg/kg vs. 0.75 mg/kg). The result of the present study will provide pharmacodynamical data for the design of future outcome studies.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 378
• Est. completion date: July 14, 2022
• Est. primary completion date: April 20, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Provision of written informed consent.

2. Aged 18 years or older, male or female.

3. Documented stable coronary artery disease (SCAD) or non-ST-segment elevation acute coronary syndromes (NSTE-ACS).

4. Plan to undergo elective trans-radial coronary angiography with or without subsequent PCI.

5. No fibrinolytic, or anticoagulant, or parenteral antiplatelet therapy within 7 days of screening.

6. Negative cardiac troponin test within 7 days of screening.

7. Trans-radial approach successfully established.

8. Females who are either post-menopausal > 1 year or surgically sterile.

Exclusion Criteria:

1. Recent (within 30 days of screening) acute myocardial infarction, including ST-segment elevation myocardial infarction or non-ST-segment elevation myocardial infarction.

2. The aim of the index coronary angiography is to undergo primary PCI or early PCI for acute coronary syndromes.

3. Any indications other than coronary artery disease (e.g., atrial fibrillation, prosthetic heart valve, venous thromboembolism, ventricular thrombosis, et al) for fibrinolytic or anticoagulant treatment during study period.

4. Planned use of any fibrinolytic or antithrombotic agents, with the exception of enoxaparin, aspirin, clopidogrel, and ticagrelor during study period.

5. Planned coronary artery bypass graft (CABG) during study period.

6. Increased bleeding risk, including

• any history of intracranial, intraocular, retroperitoneal, or spinal bleeding;

• recent (within 30 days of screening) gastrointestinal (GI) bleeding;

• recent (within 30 days of screening) major trauma or major surgery;

• planned surgery or other invasive procedure during study period;

• sustained uncontrolled hypertension (systolic blood pressure [SBP] > 180 mmHg or diastolic blood pressure [DBP] > 100 mmHg) within 7 days of screening;

• history of hemorrhagic disorders, e.g., haemophilia, von Willebrand's disease;

• inability to discontinue non-steroidal anti-inflammatory drugs (NSAIDs) during study period;

• platelet count less than 100,000/mm3 or hemoglobin < 10 g/dL within 7 days of screening.

7. Contraindications for enoxaparin, e.g., hypersensitivity, active bleeding, bleeding diathesis, coagulation disorders, acute infectious endocarditis, thrombocytopenia (including heparin-induced thrombocytopenia), cerebral hemorrhage, severe liver of kidney diseases, severe hypertension, stroke, retinopathy, et al.

8. History of intolerance to enoxaparin.

9. Patient requires dialysis or has a creatinine clearance < 30 mL/min as calculated by the Cockcroft-Gault equation: Clcr = (140 - Age) × WT / (72 × Scr) (× 0.85 for females), where WT is weight in kg, Scr is serum creatinine in mg/dL measured within 7 days of screening.

10. Any acute or chronic unstable conditions in the past 30 days which, in the opinion of the investigator, may either put the patient at risk or influence the result of the study, e.g., active cancer, et al.

11. Any condition that may increase the risk of non-compliance to study protocol or follow-up, e.g., history of drug addiction or alcohol abuse, et al.

12. Patients who has previously been randomized in this study.

13. Participation in another investigational drug or device study within 30 days of screening.

14. Involvement in the planning and conduct of the study (applies to investigators, contract research organization staff, and study site staff).

15. Known pregnancy, breast-feeding, or intend to become pregnant during the study period.

16. Any condition which in the opinion of the investigator would make it unsafe or unsuitable for the patient to participate in this study.

Related Conditions & MeSH terms

• Coronary Artery Disease
• Percutaneous Coronary Intervention

Intervention

Drug:
• Enoxaparin (Staged-dose PCI Group)
Enoxaparin 0.5+0.25 mg/kg administered intravenously.
• Enoxaparin (Single-dose PCI Group)
Enoxaparin 0.75 mg/kg administered intravenously.
• Enoxaparin (High-dose Group)
Enoxaparin 0.75 mg/kg administered intravenously.
• Enoxaparin (Standard-dose Group)
Enoxaparin 0.5 mg/kg administered intravenously.

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking Union Medical College Hospital

Country where clinical trial is conducted

China, 

References & Publications (46)

Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ; ACC/AHA Task Force Members; Society for Cardiovascula — View Citation

Argenti D, Hoppensteadt D, Heald D, Jensen B, Fareed J. Pharmacokinetics of enoxaparin in patients undergoing percutaneous coronary intervention with and without glycoprotein IIb/IIIa therapy. Am J Ther. 2003 Jul-Aug;10(4):241-6. — View Citation

Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Tag — View Citation

Bernat I, Horak D, Stasek J, Mates M, Pesek J, Ostadal P, Hrabos V, Dusek J, Koza J, Sembera Z, Brtko M, Aschermann O, Smid M, Polansky P, Al Mawiri A, Vojacek J, Bis J, Costerousse O, Bertrand OF, Rokyta R. ST-segment elevation myocardial infarction trea — View Citation

Caputo RP, Tremmel JA, Rao S, Gilchrist IC, Pyne C, Pancholy S, Frasier D, Gulati R, Skelding K, Bertrand O, Patel T. Transradial arterial access for coronary and peripheral procedures: executive summary by the Transradial Committee of the SCAI. Catheter — View Citation

Chen WH, Lau CP, Lau YK, Ng W, Lee PY, Yu CM, Ma E. Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention. J Invasive Cardiol. 2002 Aug;14(8):439-42. — View Citation

Chew DP, Bhatt DL, Lincoff AM, Moliterno DJ, Brener SJ, Wolski KE, Topol EJ. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation. 2001 Feb 20;103(7):96 — View Citation

Choussat R, Montalescot G, Collet JP, Vicaut E, Ankri A, Gallois V, Drobinski G, Sotirov I, Thomas D. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol. 2002 Dec 4;40(11):1943-50. — View Citation

Cohen M. The role of low-molecular-weight heparin in the management of acute coronary syndromes. J Am Coll Cardiol. 2003 Feb 19;41(4 Suppl S):55S-61S. Review. — View Citation

Collet JP, Montalescot G, Lison L, Choussat R, Ankri A, Drobinski G, Sotirov I, Thomas D. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation. 2001 Feb 6;103(5):658-63. — View Citation

Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. J Am Coll Cardiol. 1997 Jun;29(7):1474-82. — View Citation

Feldman DN, Swaminathan RV, Kaltenbach LA, Baklanov DV, Kim LK, Wong SC, Minutello RM, Messenger JC, Moussa I, Garratt KN, Piana RN, Hillegass WB, Cohen MG, Gilchrist IC, Rao SV. Adoption of radial access and comparison of outcomes to femoral access in pe — View Citation

Ferguson JJ, Dougherty KG, Gaos CM, Bush HS, Marsh KC, Leachman DR. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1994 Apr;23(5):1061-5. — View Citation

Ferrante G, Rao SV, Jüni P, Da Costa BR, Reimers B, Condorelli G, Anzuini A, Jolly SS, Bertrand OF, Krucoff MW, Windecker S, Valgimigli M. Radial Versus Femoral Access for Coronary Interventions Across the Entire Spectrum of Patients With Coronary Artery — View Citation

Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van 't Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F, Braunwald E, Harrington RA, Califf RM, Newby LK; EARLY ACS Investigators. Early versus delayed, provis — View Citation

Gurm HS, Hosman C, Share D, Moscucci M, Hansen BB; Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Comparative safety of vascular closure devices and manual closure among patients having percutaneous coronary intervention. Ann Intern Med. 20 — View Citation

Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3 Suppl):188S-203S. — View Citation

Karrowni W, Vyas A, Giacomino B, Schweizer M, Blevins A, Girotra S, Horwitz PA. Radial versus femoral access for primary percutaneous interventions in ST-segment elevation myocardial infarction patients: a meta-analysis of randomized controlled trials. JA — View Citation

Kereiakes DJ, Grines C, Fry E, Esente P, Hoppensteadt D, Midei M, Barr L, Matthai W, Todd M, Broderick T, Rubinstein R, Fareed J, Santoian E, Neiderman A, Brodie B, Zidar J, Ferguson JJ, Cohen M; NICE 1 and NICE 4 Investigators. National Investigators Col — View Citation

Kerré S, Kustermans L, Vandendriessche T, Bosmans J, Haine SE, Miljoen H, Vrints CJ, Beutels P, Wouters K, Claeys MJ. Cost-effectiveness of contemporary vascular closure devices for the prevention of vascular complications after percutaneous coronary inte — View Citation

Khambatta S, Othman H, Seth M, Lalonde T, Rosman HS, Gurm HS, Mehta RH; Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) Investigators. Association Of Bleeding Avoidance Strategies with age-related bleeding and In-hospital mortality in — View Citation

Lee MS, Applegate B, Rao SV, Kirtane AJ, Seto A, Stone GW. Minimizing femoral artery access complications during percutaneous coronary intervention: a comprehensive review. Catheter Cardiovasc Interv. 2014 Jul 1;84(1):62-9. doi: 10.1002/ccd.25435. Epub 20 — View Citation

Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH; American College of Cardiology Foundation; American — View Citation

Martin JL, Fry ET, Sanderink GJ, Atherley TH, Guimart CM, Chevalier PJ, Ozoux ML, Pensyl CE, Bigonzi F. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) s — View Citation

Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007 Mar 8;356(10):1020-9. Epub 2007 Feb 12. — View Citation

McGarry TF Jr, Gottlieb RS, Morganroth J, Zelenkofske SL, Kasparian H, Duca PR, Lester RM, Kreulen TH. The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J. 1992 Jun;123(6) — View Citation

Montalescot G, Cohen M, Salette G, Desmet WJ, Macaya C, Aylward PE, Steg PG, White HD, Gallo R, Steinhubl SR; STEEPLE Investigators. Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights — View Citation

Montalescot G, Collet JP, Tanguy ML, Ankri A, Payot L, Dumaine R, Choussat R, Beygui F, Gallois V, Thomas D. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation. 2004 Jul 27 — View Citation

Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, Bode C, Chiariello M, King SB 3rd, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR; STEEPLE Investigators. Enoxaparin versus unfractionated heparin in elective percutaneous coronary interven — View Citation

Montalescot G, Zeymer U, Silvain J, Boulanger B, Cohen M, Goldstein P, Ecollan P, Combes X, Huber K, Pollack C Jr, Bénezet JF, Stibbe O, Filippi E, Teiger E, Cayla G, Elhadad S, Adnet F, Chouihed T, Gallula S, Greffet A, Aout M, Collet JP, Vicaut E; ATOLL — View Citation

Narins CR, Hillegass WB Jr, Nelson CL, Tcheng JE, Harrington RA, Phillips HR, Stack RS, Califf RM. Relation between activated clotting time during angioplasty and abrupt closure. Circulation. 1996 Feb 15;93(4):667-71. — View Citation

Navarese EP, De Luca G, Castriota F, Kozinski M, Gurbel PA, Gibson CM, Andreotti F, Buffon A, Siller-Matula JM, Sukiennik A, De Servi S, Kubica J. Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary interventio — View Citation

Rao SV, Cohen MG, Kandzari DE, Bertrand OF, Gilchrist IC. The transradial approach to percutaneous coronary intervention: historical perspective, current concepts, and future directions. J Am Coll Cardiol. 2010 May 18;55(20):2187-95. doi: 10.1016/j.jacc.2 — View Citation

Rao SV, Ou FS, Wang TY, Roe MT, Brindis R, Rumsfeld JS, Peterson ED. Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry. JACC Cardiovasc Int — View Citation

Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S; ESC Scientific Document Group . 201 — View Citation

Sachdeva S, Saha S. Transradial approach to cardiovascular interventions: an update. Int J Angiol. 2014 Jun;23(2):77-84. doi: 10.1055/s-0034-1372243. Review. — View Citation

Samama MM, Gerotziafas GT. Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost. 2000;26 Suppl 1:31-8. Review. — View Citation

Sanborn TA, Tomey MI, Mehran R, Généreux P, Witzenbichler B, Brener SJ, Kirtane AJ, McAndrew TC, Kornowski R, Dudek D, Nikolsky E, Stone GW. Femoral vascular closure device use, bivalirudin anticoagulation, and bleeding after primary angioplasty for STEMI — View Citation

Sanchez-Pena P, Hulot JS, Urien S, Ankri A, Collet JP, Choussat R, Lechat P, Montalescot G. Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. Br J Clin Pharmacol. 2 — View Citation

Silvain J, Beygui F, Ankri A, Bellemain-Appaix A, Pena A, Barthelemy O, Cayla G, Gallois V, Galier S, Costagliola D, Collet JP, Montalescot G. Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test. J Am Coll Card — View Citation

Silvain J, Beygui F, Barthélémy O, Pollack C Jr, Cohen M, Zeymer U, Huber K, Goldstein P, Cayla G, Collet JP, Vicaut E, Montalescot G. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic re — View Citation

Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW; Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators. Biv — View Citation

Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Mor — View Citation

Tolleson TR, O'Shea JC, Bittl JA, Hillegass WB, Williams KA, Levine G, Harrington RA, Tcheng JE. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. J Am Coll Cardiol. 2003 — View Citation

Valgimigli M, Gagnor A, Calabró P, Frigoli E, Leonardi S, Zaro T, Rubartelli P, Briguori C, Andò G, Repetto A, Limbruno U, Cortese B, Sganzerla P, Lupi A, Galli M, Colangelo S, Ierna S, Ausiello A, Presbitero P, Sardella G, Varbella F, Esposito G, Santare — View Citation

Wimmer NJ, Secemsky EA, Mauri L, Roe MT, Saha-Chaudhuri P, Dai D, McCabe JM, Resnic FS, Gurm HS, Yeh RW. Effectiveness of Arterial Closure Devices for Preventing Complications With Percutaneous Coronary Intervention: An Instrumental Variable Analysis. Cir — View Citation

* Note: There are 46 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Major adverse cardiac events (MACE) in the High-dose vs. the Standard-dose group.	The proportion of patients with the composite of death, or myocardial infarction, or urgent coronary revascularization, or definite or probable stent thrombosis in the High-dose vs. the Standard-dose group.	Up to 24 hours.
Other	Major adverse cardiac events (MACE) in the Staged-dose PCI vs. the Single-dose PCI group.	The proportion of patients with the composite of death, or myocardial infarction, or urgent coronary revascularization, or definite or probable stent thrombosis in the Staged-dose PCI vs. the Single-dose PCI group.	Up to 24 hours.
Other	Thrombolysis in myocardial infarction (TIMI) major or minor bleeding in the High-dose vs. the Standard-dose group.	The proportion of patients with the composite of TIMI major or minor bleeding in the High-dose vs. the Standard-dose group.	Up to 24 hours.
Other	Thrombolysis in myocardial infarction (TIMI) major or minor bleeding in the Staged-dose PCI vs. the Single-dose PCI group.	The proportion of patients with the composite of TIMI major or minor bleeding in the Staged-dose PCI vs. the Single-dose PCI group.	Up to 24 hours.
Primary	Anti-Xa level (CAG-90 min) in the High-dose vs. the Standard-dose group.	The anti-Xa level (CAG-90 min) in the High-dose vs. the Standard-dose group.	At 90 min after the first dose enoxaparin is given.
Primary	Anti-Xa level (CAG-90 min) in the Staged-dose PCI vs. the Single-dose PCI group.	The anti-Xa level (CAG-90 min) in the Staged-dose PCI vs. the Single-dose PCI group.	At 90 min after the first dose enoxaparin is given.
Secondary	Anti-Xa level (CAG-10 min) in the High-dose vs. the Standard-dose group.	The anti-Xa level (CAG-10 min) in the High-dose vs. the Standard-dose group.	At 10 min after the first dose enoxaparin is given.
Secondary	Anti-Xa level (CAG-10 min) in the Staged-dose PCI vs. the Single-dose PCI group.	The anti-Xa level (CAG-10 min) in the Staged-dose PCI vs. the Single-dose PCI group.	At 10 min after the first dose enoxaparin is given.
Secondary	Anti-Xa level (PCI-0 min) in the Staged-dose PCI vs. the Single-dose PCI group.	The anti-Xa level (PCI-0 min) in the Staged-dose PCI vs. the Single-dose PCI group.	At 0 min (immediately before) PCI.
Secondary	Anti-Xa level (PCI-10 min) in the Staged-dose PCI vs. the Single-dose PCI group.	The anti-Xa level (PCI-10 min) in the Staged-dose PCI vs. the Single-dose PCI group.	At 10 min after the beginning of PCI.
Secondary	Anti-Xa level (PCI-End) in the Staged-dose PCI vs. the Single-dose PCI group.	The anti-Xa level (PCI-End) in the Staged-dose PCI vs. the Single-dose PCI group.	At the end of PCI.
Secondary	Target anticoagulation (CAG-90 min) in the High-dose vs. the Standard-dose group.	The rate of target anticoagulation (CAG-90 min) in the High-dose vs. the Standard-dose group.	At 90 min after the first dose enoxaparin is given.
Secondary	Target anticoagulation (CAG-90 min) in the Staged-dose PCI vs. the Single-dose PCI group.	The rate of target anticoagulation (CAG-90 min) in the Staged-dose PCI vs. the Single-dose PCI group.	At 90 min after the first dose enoxaparin is given.
Secondary	Target anticoagulation (CAG-10 min) in the High-dose vs. the Standard-dose group.	The rate of target anticoagulation (CAG-10 min) in the High-dose vs. the Standard-dose group.	At 10 min after the first dose enoxaparin is given.
Secondary	Target anticoagulation (CAG-10 min) in the Staged-dose PCI vs. the Single-dose PCI group.	The rate of target anticoagulation (CAG-10 min) in the Staged-dose PCI vs. the Single-dose PCI group.	At 10 min after the first dose enoxaparin is given.
Secondary	Target anticoagulation (PCI-0 min) in the Staged-dose PCI vs. the Single-dose PCI group.	The rate of target anticoagulation (PCI-0 min) in the Staged-dose PCI vs. the Single-dose PCI group.	At 0 min (immediately before) PCI.
Secondary	Target anticoagulation (PCI-10 min) in the Staged-dose PCI vs. the Single-dose PCI group.	The rate of target anticoagulation (PCI-10 min) in the Staged-dose PCI vs. the Single-dose PCI group.	At 10 min after the beginning of PCI.
Secondary	Target anticoagulation (PCI-End) in the Staged-dose PCI vs. the Single-dose PCI group.	The rate of target anticoagulation (PCI-End) in the Staged-dose PCI vs. the Single-dose PCI group.	At the end of PCI.